U.S. markets closed
  • S&P 500

    3,821.35
    -20.59 (-0.54%)
     
  • Dow 30

    31,802.44
    +306.14 (+0.97%)
     
  • Nasdaq

    12,609.16
    -310.99 (-2.41%)
     
  • Russell 2000

    2,202.98
    +10.77 (+0.49%)
     
  • Crude Oil

    64.82
    -0.23 (-0.35%)
     
  • Gold

    1,679.80
    +1.80 (+0.11%)
     
  • Silver

    25.21
    -0.06 (-0.23%)
     
  • EUR/USD

    1.1846
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    1.5960
    +0.0420 (+2.70%)
     
  • GBP/USD

    1.3811
    -0.0011 (-0.08%)
     
  • USD/JPY

    109.0640
    +0.1630 (+0.15%)
     
  • BTC-USD

    52,097.66
    +986.34 (+1.93%)
     
  • CMC Crypto 200

    1,056.53
    +32.33 (+3.16%)
     
  • FTSE 100

    6,719.13
    +88.61 (+1.34%)
     
  • Nikkei 225

    28,653.97
    -89.28 (-0.31%)
     

Mirum Pharmaceuticals (MIRM) in Focus: Stock Moves 5.9% Higher

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Mirum Pharmaceuticals, Inc. MIRM was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $17.45 –$25.45 in the past one-month time frame, witnessed a sharp increase yesterday.

The company has seen one negative estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So, make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Mirum Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

Mirum Pharmaceuticals, Inc. Price

Mirum Pharmaceuticals, Inc. Price
Mirum Pharmaceuticals, Inc. Price


Mirum Pharmaceuticals, Inc. price | Mirum Pharmaceuticals, Inc. Quote

Investors interested in the Medical - Biomedical and Genetics industry may consider Repligen Corporation RGEN, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.

See 8 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Repligen Corporation (RGEN) : Free Stock Analysis Report
 
Mirum Pharmaceuticals, Inc. (MIRM) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research